Therapeutic Targeting of Mitochondrial Dysfunction in Heart Failure: A Systematic Review & Meta-Analysis of Clinical Outcomes - Summary - MDSpire

Therapeutic Targeting of Mitochondrial Dysfunction in Heart Failure: A Systematic Review & Meta-Analysis of Clinical Outcomes

  • By

  • Mohammed, Omer

  • Rasheed, Shabrin Abdul

  • Arora, Ananya

  • V.S, Sharon

  • Kanniyan, Afthab Salam

  • Thomas, Shilla

  • Bhat, Basil Wahid

  • Pararath Gopalakrishnan, Venu

  • George, Jeffrey

  • Rosenzveig, Akiva

  • Nanjundappa, Aravinda

  • Kutty, Shelby

  • June 22, 2026

  • 0 min

Share

Objective:

To evaluate the impact of therapeutic agents aimed at restoring mitochondrial function on clinical outcomes in heart failure (HF) patients.

Approach:
    Key Findings:
    • Interventions significantly improved LVEF compared to baseline (SMD: 0.53; 95% CI: 0.42–0.65; p < 0.00001) and control groups (SMD: 0.42; 95% CI: 0.31–0.53).
    • Treatment reduced NYHA functional class (RR: 2.38; 95% CI: 1.48–3.84; p = 0.0004).
    • All-cause mortality was reduced (RR: 0.62; 95% CI: 0.47–0.82; p = 0.0007).
    • HF-related hospitalizations were reduced (RR: 0.60; 95% CI: 0.42–0.85; p = 0.004).
    Interpretation:

    Limitations:
    • Certainty of evidence rated as low across all outcomes due to substantial heterogeneity.
    • High risk of bias in included studies.
    Conclusion:

    Further high-quality trials are needed before firm clinical recommendations can be made.

Original Source(s)

Therapeutic Targeting of Mitochondrial Dysfunction in Heart Failure: A Systematic Review & Meta-Analysis of Clinical Outcomes

  • by Mohammed, Omer , Rasheed, Shabrin Abdul, Arora, Ananya , V.S, Sharon , Kanniyan, Afthab Salam, Thomas, Shilla , Bhat, Basil Wahid, Pararath Gopalakrishnan, Venu , George, Jeffrey , Rosenzveig, Akiva , Nanjundappa, Aravinda , Kutty, Shelby

  • June 22, 2026

Related Content

FDA Expands CAPVAXIVE Pediatric Use

Phase 3 data showed noninferior immune responses vs pneumococcal 23-valent polysaccharide vaccine in pediatric patients at increased risk.

Ex situ heart perfusion: a novel model for drug validation and translation

Effectiveness of low-dose SGLT2 inhibitors in diabetic patients with heart failure: a nationwide cohort study